BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directors.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), today announced a conference call to provide updates and discuss strategy, as well as the resignation of Thomas Farb and Agnieszka Winkler as members of the Company’s Board of Directors (the “Board”), effective December 5, 2021.

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer.

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Context Therapeutics Inc. (Nasdaq: CNTX), today announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation.

Agendia, Inc., a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint® and BluePrint® to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).

Simcere Pharmaceutical Group and Aeromics, Inc. today announced that Simcere dosed the first subjects in the SIM0307 (AER-271) Phase I study conducted in Beijing Tiantan Hospital.

Increasing demand for therapeutics with high purity, rising production of generic drugs, and growing adoption of track etched membrane in food and beverage industry are key factors driving market growth.

NRx Pharmaceuticals (NASDAQ: NRXP) today announced the conclusion of high-level meetings in Hungary that are expected to lead to utilization of ZYESAMI® (aviptadil) in that country and the pivotal clinical trial of the BriLife COVID-19 vaccine (BriLife).

Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1™) who are likely to respond to Denovo’s investigational cancer drug DB102™ for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.